We are not looking for customers. We are looking for co-builders — partners who see the same problems, share the same long-term ambition, and want to help build diagnostic technologies that could serve a billion people.
Who we work with
Back a mission-scale opportunity at the frontier of accessible diagnostics.
Bring reagent-free, point-of-care testing to your patients and your frontline.
Deploy diagnostics at population scale, where the need is greatest.
Carry a frontier portfolio into the markets you know best.
Why partner
The need for affordable, accessible diagnostics is vast and largely unmet — most acutely in the very places we were built to serve. BIQADX pairs that mission with an India-first advantage: engineered for the hardest conditions, priced for the widest reach, and ready to scale.
For investors
The market is vast and structurally underserved. Nearly half the world's population lacks access to basic diagnostics. The global in-vitro diagnostics market is large, but almost none of that value reaches the settings where the need is greatest. The diagnostic gap is not a niche — it is one of the largest unaddressed segments in global healthcare.
The architectural advantage is defensible. BIQADX is not building a cheaper version of existing technology. We are building on a different design thesis — reagent-free sensing, multi-modal signal acquisition, edge AI, and biodegradable carriers — anchored by a growing patent portfolio, with multiple applications filed and lead application under examination.
India-first is a strategic advantage. A platform proven in India's Tier-2 and Tier-3 conditions is transferable to similar settings across South Asia, Sub-Saharan Africa, and Southeast Asia.
Diligence-ready materials available under NDA. We welcome rigorous due diligence and can share investor brief, unit-economics model, IP landscape analysis, milestone roadmap, and technical documentation under appropriate confidentiality.
What you get
Access to one of the most architecturally ambitious diagnostic programs being built today — across device families, a biodegradable consumables program, and a clinical AI stack. Early partners and investors gain visibility into the development roadmap and the opportunity to shape deployment priorities.
This is not a single product — it is a platform architecture designed to generate a portfolio of devices, carriers, and intelligence services across haematology, biochemistry, immunology, infectious disease, and metabolic monitoring.
Every device deployed in an underserved setting represents a measurable expansion of diagnostic access — patients tested, conditions caught earlier, and empirical treatments avoided.
How engagement works
Tell us who you are and what you hope to build. Every enquiry reaches our team directly.
We share our direction in depth and understand your goals — investment, deployment, distribution, or research.
Where there's a fit, we shape a mission-aligned partnership for the road ahead.
Register your interest
Your interest has reached our team. We'll be in touch personally, soon.